SP-B, osteopontin and galectin-3 have an established association with pulmonary disease and may be useful biomarkers to assess the degree of pulmonary hypoplasia and pulmonary hypertension in CDH and monitor the efficacy of treatment aiming to restore normal lung airway and vascular physiology in CDH. Here, SPP1 is linked to pulmonary arterial hypertension.